Saturday 17 October 2026 Export MDXG’s income statement to Excel — free account

MiMedx Group, Inc

MiMedx Group, Inc’s revenue for fiscal 2025 (year ended December 2025) was $418.6 million, up 20.0% from fiscal 2024. In the quarter to June 2026, revenue fell 34.7%, EPS fell 242.9%, free cash flow fell 174.8% and total debt fell 6.80%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

4.43 0.25 −5.34%

Follow MDXG

Alert me

Market cap: $682.2M
P/E: 111×
Fwd P/E: −31.2×
Dividend yield: —
F-score: 5/9
Altman Z: 9.38
Beneish M: −2.68
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.43

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 22.66%

Capital & Financial Ratios $m

Market Cap 682.15

Revenue 355.17

Net Income 6.24

Free Cash Flow 44.43

Net Debt (118.63)

Current Ratio 5.33

Debt/Equity 0.08

P/E ratio 110.75

Fwd P/E (31.20)

P/S ratio 1.84

P/B ratio 3.03

Past 5Y EPS Growth —

This Y EPS Growth (123.44%)

Next Y EPS Growth 266.85%

Next Y revenue growth (35.55%)

Next 5Y EPS Growth (14.52%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 84.66%

10-year low 10-year high

P/S against its own 10 years 27.94%

10-year low 10-year high

P/B against its own 10 years 7.77%

10-year low 10-year high

EV/Sales against its own 10 years 21.05%

10-year low 10-year high

EV/FCF against its own 10 years 21.56%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	82	104	166	136
Receivables	54	56	76	41
Inventory	21	24	25	21
Other	2	8	10	7
	164	192	277	205

	2023	2024	2025	Q'26
Payables	9	7	15	8
ST’ Debt	1	1	2	2
Other	3	5	6	4
	46	46	64	38

Compound Annual Growth %

	10y	5y	3y
Sales	8.38%	11.02%	16.05%
Cash Flow	14.68%	0.00%	0.00%
Earnings	5.13%	0.00%	0.00%
Book Value	9.04%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	59	64	—	—	—
’25	88	99	114	118	419
’24	85	87	84	93	349
’23	72	81	82	87	321
’22	59	67	68	74	268
’21	60	68	63	51	242
’20	62	54	64	69	248

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	2	(10)	—	—	—
’25	5	14	29	25	74
’24	6	22	20	19	66
’23	(4)	8	13	10	27
’22	(10)	(3)	1	(6)	(18)
’21	(7)	2	6	(3)	(2)
’20	(12)	(3)	(5)	(10)	(30)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	1	(11)	—	—	—
’25	5	14	29	25	73
’24	5	21	20	19	65
’23	(5)	7	12	10	25
’22	(10)	(3)	1	(6)	(19)
’21	(9)	1	6	(4)	(5)
’20	(13)	(4)	(5)	(13)	(35)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.07)	(0.10)	—	—	—
’25	0.05	0.06	0.11	0.10	0.32
’24	0.06	0.12	0.05	0.05	0.28
’23	(0.06)	0.00	0.06	0.32	0.37
’22	(0.11)	(0.11)	(0.09)	(0.02)	(0.33)
’21	(0.09)	(0.03)	(0.04)	0.01	(0.15)
’20	(0.04)	(0.08)	(0.48)	(0.17)	(0.77)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	6.64	7.64	0.95	1.55	2.95	5.30	2.43	2.82	5.47	5.79	Analyst estimates 2026–2028 Powerpack
	High	10.02	17.47	18.25	7.95	10.38	15.99	6.35	9.27	10.14	9.71
People
People	Employees	690	—	753	696	735	811	867	895	837	808
	Revenue/emp, $m	0.32	0.00	0.48	0.43	0.34	0.30	0.31	0.36	0.42	0.52
Income, $m
Income, $m	Revenue	222	321	359	299	248	242	268	321	349	419
	Gross margin, %	86.05	89.03	89.87	85.60	84.16	83.63	81.96	83.01	82.78	82.56
	EBT	1	45	(3)	(26)	(62)	(12)	(20)	31	57	66
	EBT margin, %	0.25	14.04	(0.95)	(8.55)	(24.79)	(4.98)	(7.37)	9.53	16.42	15.83
	Net income	0	65	(30)	(26)	(49)	(12)	(20)	67	42	49
	Depreciation	7	6	7	9	9	6	4	3	6	15
Per share, $
Per share, $	Revenue	2.09	3.03	3.40	2.80	2.29	2.19	2.37	2.76	2.37	2.83
	Earnings	0.00	0.58	(0.28)	(0.23)	(0.77)	(0.15)	(0.33)	0.40	0.29	0.33
	Cash flow	0.23	0.59	0.34	(0.37)	(0.28)	(0.02)	(0.16)	0.23	0.45	0.50
	Capex	(0.07)	(0.05)	(0.09)	(0.02)	(0.04)	(0.03)	(0.01)	(0.02)	(0.01)	(0.01)
	Free cash flow	0.16	0.54	0.24	(0.39)	(0.32)	(0.05)	(0.17)	0.21	0.44	0.49
	Book value	1.26	0.70	0.47	0.32	0.00	0.00	(0.16)	1.23	1.31	1.74
	Shares, m	106	106	106	107	108	110	113	116	147	148
Valuation, ×
Valuation, ×	P/E	3,650.00	21.28	0.00	0.00	0.00	0.00	0.00	19.68	34.36	20.52
	P/S	4.19	4.29	0.53	2.71	3.96	2.75	1.25	2.85	4.05	2.39
	P/B	6.98	18.67	3.81	23.57	0.00	8,128.44	0.00	6.42	7.32	3.90
	EV/Sales	4.03	4.20	0.40	2.70	3.77	2.60	1.19	2.75	3.81	2.04
	EV/FCF	53.18	23.46	5.58	(19.39)	(26.88)	(115.34)	(16.46)	35.66	20.59	11.68
Cash, $m
Cash, $m	Operating cash flow	24	63	36	(39)	(30)	(2)	(18)	27	66	74
	Capex	(7)	(5)	(10)	(2)	(5)	(3)	(2)	(2)	(2)	(1)
	Free cash flow	17	58	26	(42)	(35)	(5)	(19)	25	65	73
Balance, $m
Balance, $m	Working capital	76	3	3	56	101	106	91	118	146	213
	Total debt	0	0	0	66	49	49	50	49	19	18
	Net debt	(34)	(27)	(45)	(3)	(47)	(38)	(16)	(33)	(86)	(148)
	Shareholders’ equity	133	74	50	34	0	0	(18)	143	193	257
Returns, %
Returns, %	ROA	0.24	41.16	(24.56)	(17.64)	(45.14)	(8.42)	(20.47)	28.37	16.87	16.02
	ROIC	0.56	61.99	(51.46)	(42.68)	0.00	0.00	0.00	21.12	34.22	36.84
	ROE	0.32	62.60	(48.57)	(60.87)	(486.62)	48,297.06	410.78	93.37	25.26	21.61

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ANL Adlai Nortye Ltd. Sponsored ADR	$710.1M	—	—	—	—	+46.03% (above 0%: growing)	—	—	Compare
OABI OmniAb, Inc.	$687.7M	— (loss-making)	— (loss-making)	+244.24% (above 0%: growing)	n/m	+211.16% (above 0%: growing)	95.45%	(49.47%)	Compare
ANNX Annexon, Inc.	$682.5M	— (loss-making)	—	—	n/m	−26.41% (below 0%: shrinking)	0.00%	0.00%	Compare
MDXG MiMedx Group, Inc	$682.2M	111×	— (loss-making)	−34.73% (below 0%: shrinking)	n/m	−174.83% (below 0%: shrinking)	68.96%	(28.69%)
CADL Candel Therapeutics, Inc.	$681.8M	— (loss-making)	— (loss-making)	0.00%	n/m	−93.35% (below 0%: shrinking)	0.00%	0.00%	Compare
PHAR Pharming Group N.V. Sponsored ADR	$681.6M	62.4×	— (loss-making)	−3.22% (below 0%: shrinking)	−57.14% (below 0%: shrinking)	−183.87% (below 0%: shrinking)	83.92%	1.44%	Compare
GYRE Gyre Therapeutics, Inc.	$678.6M	— (loss-making)	— (loss-making)	−2.12% (below 0%: shrinking)	n/m	−130.45% (below 0%: shrinking)	92.41%	(49.35%)	Compare
AURA Aura Biosciences, Inc.	$657.5M	— (loss-making)	—	—	n/m	−56.26% (below 0%: shrinking)	0.00%	0.00%	Compare
DSGN Design Therapeutics, Inc.	$655.9M	— (loss-making)	— (loss-making)	—	n/m	−7.00% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$681.7M	—	—	−1.06%	—	−41.33%	0.00%	0.00%

All 614 Biotechnology stocks →

MiMedx Group, Inc (MDXG) key facts

Strength: MiMedx Group, Inc’s revenue for fiscal 2025 (year ended December 2025) was $418.6 million, up 20.0% from fiscal 2024.
MiMedx Group, Inc (MDXG) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, MDXG traded at $4.43, a market capitalization of $682.2 million.
Return on equity was 21.6% and debt-to-equity 0.08.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 9.38 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.